While AI dominates headlines, GLP-1s offer more immediate and tangible improvements to human health and quality of life. The market impact of solving pervasive health crises like obesity, addiction, and heart disease may ultimately dwarf the current perceived value of AI.

The GLP-1 drug revolution is moving beyond weekly injections for wealthy markets. Upcoming pill-form versions will eliminate the need for refrigerated supply chains, opening up distribution in developing countries. Combined with expiring patents, this focus on form factor and cost will enable mass global adoption.

Weight-loss drugs like Ozempic have moved from a niche medical treatment to a mainstream phenomenon, with new data showing 15.2% of all American women are now taking them. This rapid, large-scale adoption signifies a major public health shift that will have downstream effects on the food, fitness, and healthcare industries.

Scott Galloway argues GLP-1 drugs (like Ozempic) will have a greater societal impact than AI. By tackling obesity, they could halve U.S. healthcare costs, help solve the deficit, and even curb addictions, making them a profoundly transformative technology.

GLP-1s are more than weight-loss aids; they are powerful anti-inflammatory agents affecting cardiovascular and neurological health. They even reduce cravings for things like gambling and cigarettes, acting as systemic moderators for entire biological systems, not just appetite.

The conversation frames GLP-1 weight-loss drugs not merely as a healthcare breakthrough but as a potential moonshot for the national economy. A mass government rollout could drastically reduce healthcare costs, improve mental health, and boost productivity, representing a powerful tool for social and economic policy with far-reaching ramifications.

Treating obesity with drugs like Wegovy for a limited time, such as two years, is akin to only treating high cholesterol temporarily. This policy ignores the medical reality that obesity is a chronic disease requiring lifelong management, not a short-term condition.

By negotiating the price of weight-loss drugs from $1,200 down to ~$200, the administration expects a net positive ROI for the government within two years. The savings from preventing obesity-related chronic illnesses will outweigh the drug costs.

Widespread obesity costs the U.S. hundreds of billions annually. A federal program to negotiate and subsidize GLP-1 drugs to a low monthly cost would be an incredibly effective investment, yielding massive returns in improved public health, productivity, and reduced healthcare spending.